Anaptysbio Inc (NQ: ANAB )

28.67 USD +0.36 (+1.27%)

Streaming Delayed Price Updated: 4:00 PM EDT, Oct 15, 2021 Add to My Watchlist

Price and Volume

Volume	122,979
Open	28.70
Bid (Size)	20.02 (1)
Ask (Size)	95.90 (1)
Prev. Close	28.31
Today's Range	28.21 - 28.82
52wk Range	17.72 - 35.85
Shares Outstanding	27,433,359
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference

September 09, 2021

FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid Tumors

August 17, 2021

Performance

YTD	+22.73%	+22.73%
1 Month	+9.22%	+9.22%
3 Month	+14.13%	+14.13%
6 Month	+31.82%	+31.82%
1 Year	+19.06%	+19.06%

More News

AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates

August 09, 2021

AnaptysBio to Present at the 2021 Jefferies Virtual Healthcare Conference

May 27, 2021

AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates

May 04, 2021

European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/MSI-H Endometrial Cancer in Europe

April 23, 2021

FDA Approves JEMPERLI (dostarlimab-gxly) for dMMR Endometrial Cancer

April 22, 2021

AnaptysBio Announces Appointment of Oleg Nodelman to Board of Directors

April 12, 2021

AnaptysBio Reveals Updated Imsidolimab Data In Severe Form Of Psoriasis

October 04, 2021

AnaptysBio-Generated Antibody Scores Second FDA Approval For Solid Tumor Indication

August 18, 2021

AnaptysBio Breaks Below 200-Day Moving Average - Notable for ANAB

July 26, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.